News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 20/01/2026			5-day change	1st Jan Change
207,000.00 ^KRW	+0.24%		-3.27%	+14.36%

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-08	Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe	AQ
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-02	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI
01-02	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
01-01	Celltrion Inc U.S. unit Celltrion USA signs production contract with Eli Lilly worth 473 million USD	RE
12-21	Samsung Biologics to buy US drug production facility from GSK for $280 million	RE
12-18	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
12-10	Celltrion, Inc. announces Annual dividend	CI
12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI
11-26	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	CI
11-19	Celltrion to invest up to $478 million to expand US factory in response to tariffs	RE
11-18	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	CI
11-18	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	CI
11-14	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Prime Medicine Q3 net loss narrows	RE
11-05	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
30/10/25	U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	CI
22/10/25	Celltrion to sell 746 million won worth of own shares	RE
21/10/25	Celltrion's Q3 Operating Income, Sales Rise	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Filters